Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis.
BACKGROUND
Post kala azar dermal leishmaniasis (PKDL) is a disease that appears after treatment of visceral leishmaniasis (VL). The highest incidence of PKDL in the world is in Sudan. Many patients heal spontaneously within 6 months but those who don't are difficult to treat, often requiring months of daily injections. These patients harbour parasite in their skin and are believed to be a source of infection and possibly epidemics. Present treatment modalities of PKDL are inadequate and impractical due to cost, duration of treatment required and side effects. New approach for treatment of PKDL is required. A joint meeting of the UNICEF/UNDP/World Bank/WHO Special Programme for research and training in Tropical Disease (TDR) and the Infectious Disease Research Institute (IDRI) Seattle, USA was held to review the progress of therapeutic vaccines and plan the development of treatment modalities for PKDL.


METHODS
The history of leishmaniasis vaccine development for prophylaxis and therapy was reviewed. Other than previous infection - simulated by inoculation of live Leishmania as a vaccine (leishmanization), none of the preparations of killed parasite with or without adjuvants have shown significant prophylactic efficacy. Killed L. major absorbed with alum and mixed with BCG remains to be tested as a prophylactic vaccine.


RESULTS
Killed parasite preparations i.e. L. mexicana mixed with BCG and L. amazonensis (combined with low dose of antimonial), have shown efficacy in immunotherapy and immuno-chemotherapy, respectively. In addition combined full antimonial plus alum-absorbed autoclaved L. major vaccine has been shown to significantly improve therapy of refractory PKDL patients. These are all crude preparations of parasites and are difficult to define and standardize. However, there is now a new, second generation vaccine, Leish-111f + MPL-SE, composed of a recombinant protein comprising three leishmanial antigens and a defined adjuvant in clinical development.


CONCLUSIONS
Immuno-chemotherapy has the potential of becoming a practical and affordable treatment modality for PKDL and other forms of leishmaniasis. The encouraging results with alum-autoclaved L. major + antimonial should be pursued. However, before further trials, availability of the vaccine and its production under Good Manufacturing Product, hence quality control must be assured. Following satisfactory safety profile of Leish-111f+MPL-SE, clinical trials using this vaccine initially with antimonials should be initiated. Similarly immunotherapy of VL should be considered with the view to controlling development of PKDL. Some immunological studies are required prior to initiation of immunotherapy in VL patients.
Ghalib
Hashim
H
Centre for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran. modabberf@yahoo.com.
Modabber
Farrokh
F
Mem Inst Oswaldo Cruz. 2004 Feb;99(1):57-62
15057348
Clin Infect Dis. 2006 Mar 1;42(5):608-13
16447104
Mol Biochem Parasitol. 1997 Nov;89(2):179-93
9364964
Ann Trop Med Parasitol. 2002 Dec;96(8):765-72
12625930
Trans R Soc Trop Med Hyg. 2003 May-Jun;97(3):365-8
15228261
Infect Immun. 2002 Jun;70(6):2828-36
12010969
J Clin Invest. 1993 Jul;92(1):324-9
8326000
Clin Dermatol. 1996 Sep-Oct;14(5):503-12
8889328
Eur J Immunol. 1997 Oct;27(10):2634-42
9368620
Clin Exp Immunol. 2005 May;140(2):349-53
15807861
Trends Parasitol. 2005 May;21(5):244-9
15837614
Lancet. 1998 May 23;351(9115):1540-3
10326536
Infect Immun. 2001 Jun;69(6):4103-8
11349082
Trans R Soc Trop Med Hyg. 2003 Jul-Aug;97(4):469-72
15259484
Lancet. 2000 Nov 4;356(9241):1565-9
11075771
Braz J Infect Dis. 2001 Aug;5(4):223-32
11712967
Infect Immun. 1998 Jul;66(7):3279-89
9632596
Vaccine. 2005 May 25;23(28):3642-8
15882524
Clin Microbiol Rev. 2006 Jan;19(1):111-26
16418526
Vaccine. 1999 Feb 5;17(5):466-72
10073725
Ann Trop Med Parasitol. 2005 Sep;99(6):563-9
16156969
J Immunol. 1998 Dec 1;161(11):6171-9
9834103
Trop Med Int Health. 2001 Sep;6(9):743-4
11555443
J Infect Dis. 2006 Oct 15;194(8):1151-9
16991091
Trans R Soc Trop Med Hyg. 2005 Aug;99(8):593-8
15893351
Am J Trop Med Hyg. 1994 Dec;51(6):826-36
7810819
J Immunol. 1999 Oct 15;163(8):4481-8
10510390
Infect Immun. 2002 Aug;70(8):4215-25
12117930
Int J Dermatol. 2002 Feb;41(2):73-8
11982640
Lancet Infect Dis. 2003 Feb;3(2):87-98
12560194
J Exp Med. 1995 Apr 1;181(4):1527-37
7699334
J Immunol. 1996 Dec 1;157(11):5034-41
8943412
Vaccine. 2001 May 14;19(25-26):3485-92
11348715
Trends Microbiol. 2002;10(10 Suppl):S32-7
12377566